NeuroSense Therapeutics (NASDAQ:NRSN) Given “Hold” Rating at Maxim Group

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “hold” rating restated by research analysts at Maxim Group in a report issued on Monday,Benzinga reports.

NeuroSense Therapeutics Stock Performance

NRSN stock opened at $1.08 on Monday. The stock’s 50 day simple moving average is $1.12 and its 200 day simple moving average is $1.03. The company has a market cap of $14.76 million, a P/E ratio of -1.27 and a beta of 1.38. NeuroSense Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.33.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. XTX Topco Ltd acquired a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned approximately 0.24% of NeuroSense Therapeutics as of its most recent filing with the Securities and Exchange Commission. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.